Advertisement

Topics

3SBio Company Profile

21:52 EDT 19th June 2018 | BioPortfolio

Shenyang Sunshine Pharmaceutical Company Limited (SUNSHINE) is an integrated biopharmaceutical company engaged in research/development, manufacture and marketing/sales of biopharmaceutical products in China. Our recombinant, or genetically engineered, protein-based products and product candidates are designed to address large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious disease. We began operations in 1993. Currently, our principal products are EPIAO®, TPIAO®, INTEFEN® and INLEUSIN®. SUNSHINE is now one of the largest biopharmaceutical companies in China in terms of market shares, growth and profitability. Manufacturing facilities Our clinical and commercial manufacturing operations are based in Shenyang, China, where our Chinese current Good Manufacturing Practice, or cGMP, certified, 3,000 square meters, and state-of-the-art facility resides. Our manufacturing facilities consist of on-site bulk manufacturing, formulation, fill, finishing and packaging activities for EPIAO, TPIAO, INTEFEN and INLEUSIN. With these facilities, we are able to produce our products and product candidates for both clinical and commercial purposes. We plan to expand our plant in Shenyang to increase our manufacturing capacity and take further advantage of our favorable cost structure.

The sales and marketing team We maintain a sales and marketing force in 18 provinces and major cities in China, including Beijing and Shanghai and Guangzhou. Our over 150 sales and marketing professionals market, and our network of approximately 80 distributors sell our principal products to healthcare providers including, based on our internal estimates, approximately 800 hospitals, clinics and dialysis centers. Our sales force in China benefits from over ten years of experience in marketing protein-based therapeutics. As a result of our history as a provider of protein therapeutics to the Chinese market, we believe our Shenyang Sunshine brand is widely recognized throughout the PRC for quality and reliability.

Research and development Our research and development team consisted of many research personnel and medical professionals, including two PhDs, two MDs and three holders of master’s degrees and many of whom have years of experience in the healthcare and biotechnology research fields, including experience working in research institutions and hospitals and in proceeding through the SFDA drug approval process.

Our product pipeline We focus our research and development efforts on both novel and validated protein-based therapeutics for the treatment of diseases in the areas of nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Our product pipeline, which we expect will be a key contributor to our future growth, consists of six product candidates in various stages of development. We employ a market-driven approach to our research and development efforts, and our team utilizes the latest molecular biology and biochemical techniques and technologies to develop promising product candidates. Our diversified product pipeline includes a number of next-generation protein-based therapeutics including NuPIAO, our second generation EPIAO product candidate; NuLeusin, our next-generation Inleusin product candidate; TPIAO for the treatment of ITP; a human papilloma virus, or HPV, vaccine for the prevention of cervical cancer; and an anti-TNF humanized monoclonal antibody product candidate for the treatment of rheumatoid arthritis and other autoimmune diseases. We believe that each of these product candidates, if successfully developed and approved, would address significant market opportunities. For all of our programs, we conduct extensive preclinical and clinical trials in order to generate safety and efficacy data to support a filing for approval as required to the SFDA.

Location

No. 3 A1, Road 10
Shenyang
110027
China

Contact

Phone: (86-24) 2581-1820
Fax: 86 24 2581 1821


News Articles [14 Associated News Articles listed on BioPortfolio]

3SBio Approved to Market Once-Weekly Type 2 Diabetes Treatment in China

3SBio reported the CFDA formally approved Bydureon®, its once-weekly Glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes treatment. In 2016, 3SBio in-licensed China rights to Bydu...

3SBio to Market Japanese Pruritis Treatment in China

3SBio of Shenyang in-licensed China rights to a pruritis (itching) treatment developed by Japan's Toray Industries. TRK-820 is a highly selective opioid receptor agonist that is intended to treat the ...

Refuge Biotechnologies Closes $25 Million Series B from Chinese Investors

Refuge Biotechnologies, a cell therapy company based in California bay area, received $25 million series B. The round was led by 3SBio and Sequoia China and followed by new investors Danhua Capital (D...

Refuge Bio raises $25M from funding round to advance CAR-T programs

Refuge Biotechnologies will receive $25 million from a Series B financing round led by Chinese investors 3SBio and Sequoia Ch -More- 

Refuge Biotechnologies Completes $25 Million Series B Financing, Appoints CSO to Advance the ...

The Series B financing was led by 3SBio and Sequoia China, with participation from new investors Danhua Capital (DHVC), Sangel Capital and Ocean Pine Healthcare Read more...

BRIEF—Licensing deal in China for Toray's anti-itching drug Remitch

Tokyo-based Toray Industries and China’s 3SBio have agreed a licensing deal for the antipruritic drug…

Refuge Biotechnologies Raises $25 Million With Support from Chinese Investors

Chinese investment firms 3SBio and Sequoia China joined a team of other investors to bankroll California-based Refuge Biotechnologies, Inc.’s $25 million funding round to support its gene therapy tr...

Refuge Bio Turns to China for $25M Financing of Precision CRISPR R&D

Refuge Biotechnologies, a company researching ways to use CRISPR gene editing to make cancer treatment more precise, has raised $25 million in financing to continue work on its preclinical drug pipeli...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

3SBio

Shenyang Sunshine Pharmaceutical Company Limited (SUNSHINE) is an integrated biopharmaceutical company engaged in research/development, manufacture and marketing/sales of biopharmaceutical products ...

More Information about "3SBio" on BioPortfolio

We have published hundreds of 3SBio news stories on BioPortfolio along with dozens of 3SBio Clinical Trials and PubMed Articles about 3SBio for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of 3SBio Companies in our database. You can also find out about relevant 3SBio Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Corporate Database Quicklinks



Searches Linking to this Company Record